Development and validation of a recurrent Clostridium difficile risk‐prediction model
- 4 April 2014
- journal article
- research article
- Published by Wiley in Journal of Hospital Medicine
- Vol. 9 (7) , 418-423
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (rCDI) affects 10% to 25% of patients with initial CDI (iCDI). Initiation of new therapies that reduce recurrences rests on identifying patients at high risk for rCDI at iCDI onset.OBJECTIVE: To develop a predictive model for rCDI based on factors present at iCDI onset.DESIGN: Retrospective cohort study.SETTING: Large urban academic medical center.PATIENTS: All adult patients with an inpatient iCDI from January 1, 2003 to December 31, 2009.INTERVENTION: None.MEASUREMENTS: Positive toxin assay for C difficile with no C difficile infection in the previous 60 days constituted iCDI. Repeat positive toxin within 42 days of stopping iCDI treatment defined rCDI. Three demographic, 13 chronic, and 12 acute disease characteristics, and 7 processes of care prior to or at the onset of iCDI, were assessed for association with rCDI. A logistic regression model to identify predictors for rCDI was developed and cross‐validated.RESULTS: Among the 4196 patients enrolled, 425 (10.1%) developed rCDI. Six factors (case status as community‐onset healthcare‐associated, ≥2 hospitalizations in the prior 60 days, new gastric acid suppression, fluoroquinolone and high‐risk antibiotic use at the onset of iCDI, age) predicted rCDI in multivariate analyses, whereas intensive care unit stay appeared protective. The model achieved moderate discrimination (C statistic 0.643) and calibration (Brier score 0.089). Its negative predictive value was 90% or higher across a wide range of risk.CONCLUSIONS: Among patients hospitalized with rCDI, multiple factors present at the onset of iCDI increased the risk for rCDI. Recognizing patients at high‐risk for rCDI can help clinicians tailor early treatment and prevention. Journal of Hospital Medicine 2014;9:418–423. © 2014 Society of Hospital MedicineKeywords
Funding Information
- Cubist Pharmaceuticals
This publication has 29 references indexed in Scilit:
- Burden of Clostridium difficile on the Healthcare SystemClinical Infectious Diseases, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionNew England Journal of Medicine, 2011
- Increase in AdultClostridium difficile–related Hospitalizations and Case-Fatality Rate, United States, 2000–2005Emerging Infectious Diseases, 2008
- Short- and Long-Term Attributable Costs of Clostridium difficile-Associated Disease in Nonsurgical InpatientsClinical Infectious Diseases, 2008
- The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic ConsequencesInfection Control & Hospital Epidemiology, 2007
- Clostridium difficileInfection in Patients Discharged from US Short-stay Hospitals, 1996–20031Emerging Infectious Diseases, 2006
- A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and MortalityNew England Journal of Medicine, 2005
- An Epidemic, Toxin Gene–Variant Strain ofClostridium difficileNew England Journal of Medicine, 2005
- Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severityCanadian Medical Association Journal, 2004